Immunohematology Market Analysis

Immunohematology Market Analysis

The reagents segment in the immunohematology market was valued at USD 1.5 billion in 2020. Reagents are primarily used in the immunohematology to analyze the ABO system, determination of group and Rh phenotype, infrequent groups, identification of infrequent antibodies, human antiglobulin, and others. As healthcare providers seek to maximize their output volume of results, the requirement of reagents also increases. Further, the rapid market demand for reagents segment can be attributed to the increasing demand of haematology tests, rising prevalence of hematological disorders as well as increasing blood donation.

The polymerase chain reaction (PCR) segment accounted for USD 857.9 million in 2020. Through PCR, multiple copies of genetic material (DNA or RNA) are generated to detect the viral load. The DNA based methods are essential for immunohematology typing. Further, the PCR segment is driven by the rising number of serological tests and increase in the prevalence of hematological disorders will fuel the industry progression.
 

The hospital segment dominated more than 54.3% of the market share in 2020. The growing number of surgical procedures in hospitals has led to an increased demand for blood transfusion, thereby increasing the number of immunohematology tests, further stimulating the market value. Furthermore, automation of immunohematology devices leads to faster results with minimal errors, the development of public and private healthcare settings worldwide will further increase the industry size.

North America immunohematology market is projected to witness 3.7% growth rate through 2027 on account of the high prevalence of leukemia in the North American region. According to the Leukemia & Lymphoma Society (LLS), approximately 376,508 people are living with leukemia in the U.S., and in 2020, 60,530 new cases were reported. Moreover, the availability of well-established healthcare infrastructure and ongoing clinical trials for the treatment of leukemia in the U.S. will propel the industry of immunohematology.